HighLife

HighLife is a medical technology company based in Paris, France, with a manufacturing facility in Irvine, California. Founded in 2010, it focuses on developing innovative transcatheter treatment solutions for heart valve diseases, particularly mitral regurgitation. This condition occurs when the heart's mitral valve does not close properly, leading to potential complications if untreated. The company's flagship product is a transcatheter mitral valve replacement system (TSMVR), designed for implantation in a beating heart through a minimally invasive procedure. This valve-in-ring technology allows for the preservation of the native valve structure while reducing patient trauma compared to traditional surgery. HighLife is currently conducting clinical evaluations and pivotal studies in Europe, the USA, and Australia, and has received FDA Breakthrough Device designation and ISO 13485 certification for its quality management system. The company collaborates with healthcare providers and holds a licensing agreement for the Chinese market, aiming to improve outcomes for patients with moderate to severe mitral regurgitation.

• Employees 67
• Founded 2010
• Annual Revenue $4900000
• Total Funding $50331104